Basic information |
Metabolite name | 1-Methylhistidine |
HMDB0000001 | |
C01152 | |
92105 | |
Synonyms | NA |
No. of studies | 12 |
Relationship between 1-Methylhistidine and depression (count: 12) |
Study | Study Type | Comparison groups | Tissue | Organism | Up/Down regulated |
Study M026 | Type1 | CUMS group vs. control group | Urine | Wistar rat | Up |
Study M101 | Type1 | CSD group vs. control group | Faece | C57BL/6 mouse | Down |
Study M109 | Type1 | PPD group vs. HC and PPWD group | Urine | Human | Up |
Study M1142 | Type2 | MDD group, after intermittent theta burst stimulation vs. baseline | Plasma | Human | Up |
Study M544 | Type1 | PSD group vs. stoke group | Plasma | Human | Up |
Study M577 | Type1 | male depression group vs. male control group, aged 20-29 | Plasma | Human | Unknown |
Study M577 | Type1 | male depression group vs. male control group, aged 40-49 | Plasma | Human | Unknown |
Study M577 | Type1 | female depression group vs. female control group, aged 30-39 | Plasma | Human | Unknown |
Study M577 | Type1 | female depression group vs. female control group, aged 40-49 | Plasma | Human | Unknown |
Study M712 | Type1 | depression group vs. control group | Hippocampus | Cynomolgus monkey | Down |
Study M737 | Type1 | IBS-D group vs. control group | Urine | Human | Down |
Study M867 | Type2 | CUMS + Baihe-Dihuang Tang group vs. CUMS group | Plasma | Sprague-Dawley rat | Unknown |
Study M908 | Type3 | post-ketamine treatment vs. baseline | Cerebrospinal fluid | Human | Down |
Study M911 | Type1 | CUS group vs. control group | Serum | Sprague-Dawley rat | Up |
Study M975 | Type1 | CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
Study M975 | Type2 | CUMS + high dose of Yang-Xin-Jie-Yu Decoction group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
Study M975 | Type2 | CUMS + low dose of Yang-Xin-Jie-Yu Decoction group vs. CUMS group | Urine | Sprague-Dawley rat | Down |
Study M975 | Type2 | CUMS + fluoxetine group vs. CUMS group | Urine | Sprague-Dawley rat | Down |